Join experts, Joseph Zabinski, PhD, MEM, and Jonathan Kish, PhD, MPH, for a discussion on how research groups are driving awareness, funding, and new research of orphan and rare diseases.

There are over 7,000 rare and orphan diseases known to impact approximately 1 in 17 individuals globally, or 50 million in the EU and USA alone. The development of safe, effective, and accessible therapies against these diseases has been challenged by manufacturing, clinical and regulatory hurdles. Despite these obstacles, increased awareness, greater funding, and new research technologies are driving discoveries in this area. Join this webinar to learn how various research groups are working in this space.

Dr. Zabinski discusses how Artificial Intelligence (AI) and Real-World Datasets (RWD) can work in synergy to address many of the challenges facing rare disease researchers, including better describing real-world epidemiology; identifying meaningful patterns in rare disease patient journeys; and assisting in finding patients, plus those not yet diagnosed. This presentation will briefly explore the ways AI and RWD together can enhance visibility into patient trajectories, improve rare disease patient identification for clinical trial recruitment and observational research, and shorten time to diagnosis.

Dr. Kish discusses how precision medicine is redefining how we evaluate and treat rare diseases. No longer is cancer defined by its organ of origin, tissue or cell type but rather its genotype. Over just a few decades lung cancer has been transformed from one disease affecting 100,000+ in the U.S. annually to dozens of cancers that each inflict just a few thousand. But, finding patients and RWD to improve outcomes can be challenging. Learn how Cardinal Health Real-World Evidence and Insights takes a decentralized approach to identify hard to find patients and RWD.

Key Topics Include:

  • The value of RWD and AI in enhancing real-world rare disease epidemiology
  • Real-world use cases for addressing unique challenges in clinical development for rare diseases
  • How AI and RWD can be used to find rare disease patients, including those without a diagnosis
  • Decentralized community provider networks
  • Case Study – How RWD can help solve challenges in rare patient populations
  • How to apply innovative research methodology
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.


To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.


Managing Director of AI & Personalized Medicine
Data Solutions

Dr. Joseph Zabinski is Managing Director of AI & Personalized Medicine at OM1. He specializes in applications of advanced analytics to real-world data in healthcare and life science contexts. He holds a master’s degree in engineering management from Dartmouth College, and a doctorate in health analytics from the School of Public Health at UNC.

Senior Director
Real-World Evidence and Insights
Cardinal Health

Jonathan Kish, PhD, MPH is Senior Director and Team Lead of Real-World Evidence & Insights at Cardinal Health. Dr. Kish is an epidemiologist by training and in his role he oversees a team responsible for retrospective and prospective research for Cardinal Health and biopharma manufacturers.

Production Partner


With specialization in chronic conditions, OM1 leverages its extensive, specialty clinical networks and an artificial intelligence (AI) platform to offer enriched health care datasets, research analytics, data modeling, decision support, and retrospective and prospective clinical studies.

Cardinal Health

Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care.

Additional Content From OM1

Additional Content From Cardinal Health

Additional Content From

Additional Content From HealthEconomics.Com

Related Content

Integrating Patient Engagement and Trainee Development in Pre-Clinical Research

Integrating Patient Engagement and Trainee Development in Pre-Clinical Research

Christopher Perry, PhD discusses how his laboratory aims to discover mechanisms by which metabolic dysfunction causes muscle weakness and apply these findings to develop new therapies for muscle disorders. Homira Osman, PhD provides a particular focus on leveraging scientific findings for practice and policy and linking trainees with patient communities.